```html

SARS‑CoV‑2 Infection (COVID‑19) – A Comprehensive Medical Guide

Overview

SARS‑CoV‑2 (Severe Acute Respiratory Syndrome Coronavirus 2) is the virus that causes COVID‑19, a respiratory illness that emerged in late 2019. The virus spreads primarily through respiratory droplets, aerosols, and, less commonly, fomites. As of mid‑2026, more than 770 million confirmed cases and over 7 million deaths have been reported worldwide [WHO, 2026]. While most infections are mild, the disease can be severe or fatal, especially in older adults and people with underlying health conditions.

The pandemic has affected every continent, but incidence varies by region, vaccination coverage, and public‑health measures. In the United States, roughly 105 million cases have been documented, with an overall case‑fatality rate of about 1 %—much lower than early estimates thanks to vaccination and improved clinical care [CDC, 2025].

Symptoms

COVID‑19 presents with a broad spectrum of clinical features that can appear 2–14 days after exposure. Symptoms may be mild, moderate, or severe, and some patients remain asymptomatic.

Common (≥ 10 % of cases)

• Fever or chills – usually 38 °C (100.4 °F) or higher.
• Cough – dry or productive.
• Fatigue – persistent tiredness not relieved by rest.
• Loss of taste or smell (anosmia/ageusia) – often sudden.
• Headache – can be mild to severe.
• Sore throat – irritation of the throat.
• Muscle or body aches – myalgia.

Less common (1‑10 % of cases)

• Congestion or runny nose.
• Nausea, vomiting, or diarrhea.
• Chest tightness or pain.
• Shortness of breath (dyspnea), especially on exertion.
• Skin rashes, “COVID toes” (chilblain‑like lesions).

Severe symptoms (require urgent medical attention)

• Difficulty breathing or shortness of breath at rest.
• Persistent chest pain or pressure.
• New confusion or inability to stay awake.
• Blue‑tinged lips or face (cyanosis).
• Rapid worsening after a few days of mild illness (“second‑week crash”).

Causes and Risk Factors

Viral Cause

SARS‑CoV‑2 is an enveloped, single‑stranded RNA virus belonging to the beta‑coronavirus family. The spike (S) protein binds to the ACE2 receptor on human cells, facilitating entry and replication. Variants (Alpha, Delta, Omicron, etc.) differ in transmissibility and immune evasion but all cause COVID‑19.

Risk Factors for Severe Disease

• Age: Adults ≥ 65 years have a 5‑10‑fold higher risk of hospitalization.
• Underlying medical conditions:
  • Cardiovascular disease (e.g., hypertension, heart failure).
  • Chronic lung disease (COPD, asthma, interstitial lung disease).
  • Diabetes mellitus (type 1 or type 2).
  • Obesity (BMI ≥ 30 kg/m²).
  • Chronic kidney disease, liver disease, immunocompromise (cancer, HIV, transplant).
• Pregnancy: Increased risk of ICU admission and ventilation.
• Socio‑economic factors: Crowded housing, limited access to health care, and occupational exposure raise infection risk.

Diagnosis

Clinical Evaluation

Healthcare providers assess exposure history, symptom onset, and severity. Physical examination may reveal fever, tachypnea, reduced oxygen saturation, or lung crackles.

Laboratory Tests

• RT‑PCR (reverse transcription polymerase chain reaction): Gold‑standard molecular test; detects viral RNA from nasopharyngeal, nasal, or saliva samples. Sensitivity > 95 % when performed correctly [CDC, 2024].
• Rapid Antigen Tests: Provide results in 15‑30 minutes. Specificity > 98 %, sensitivity 70‑85 % (higher in symptomatic individuals with high viral load).
• Serology (antibody) tests: Used to assess prior infection or vaccine response, not for acute diagnosis.

Imaging & Additional Labs (for moderate–severe cases)

• Chest X‑ray: May show bilateral infiltrates.
• CT scan: Ground‑glass opacities are characteristic.
• Blood work: CBC (lymphopenia), elevated CRP, D‑dimer, ferritin, and liver enzymes can indicate inflammation or coagulopathy.

Treatment Options

Outpatient (Mild to Moderate) Care

• Antiviral therapy:
  • Paxlovid (nirmatrelvir + ritonavir) – 300 mg/100 mg twice daily for 5 days, started within 5 days of symptom onset. Reduces hospitalization by ~89 % [NEJM, 2022].
  • Molnupiravir – 800 mg twice daily for 5 days; modest reduction in severe outcomes.
• Monoclonal antibodies: Effective against specific variants; examples include bebtelovimab (US) and tixagevimab/cilgavimab (Evusheld) for prophylaxis.
• Supportive care: Hydration, antipyretics (acetaminophen), rest, and monitoring of oxygen saturation.

Hospitalized (Severe) Care

• Oxygen therapy: Nasal cannula, high‑flow nasal oxygen, or non‑invasive ventilation as needed.
• Corticosteroids: Dexamethasone 6 mg daily for up to 10 days (or equivalent) reduces mortality in patients requiring supplemental O₂ [RECOVERY Trial, 2020].
• Antiviral plus anti‑inflammatory combo: Remdesivir IV (200 mg day 1, then 100 mg daily) for up to 10 days, especially when started early.
• Immunomodulators: Tocilizumab or baricitinib for patients with rapid respiratory decline and elevated inflammatory markers.
• Anticoagulation: Prophylactic low‑molecular‑weight heparin to prevent thromboembolic events; therapeutic dosing if D‑dimer is markedly elevated or thrombosis is confirmed.
• Advanced support: Mechanical ventilation, extracorporeal membrane oxygenation (ECMO) for refractory hypoxemia.

Lifestyle & Adjunct Measures

• Regular breathing exercises (e.g., pursed‑lip breathing) to improve ventilation.
• Nutrition rich in protein, vitamin D, and antioxidants.
• Avoidance of smoking and alcohol excess, which impair immune function.

Living with SARS‑CoV‑2 Infection (COVID‑19)

Self‑Monitoring

• Check temperature twice daily.
• Use a pulse oximeter; seek care if SpO₂ drops below 94 % at rest.
• Keep a symptom diary (e.g., headache severity, cough frequency).

Isolation Guidelines

Follow CDC recommendations: at least 5 days from symptom onset (or positive test if asymptomatic) and 24 hours fever‑free without antipyretics. Continue wearing a mask in public for an additional 5 days.

Physical Activity

Gradually resume light activity (walking, stretching) after the acute phase. For athletes or those with “long COVID,” a structured, supervised exercise program is advisable.

Nutrition & Hydration

• Aim for 2‑3 L of fluids per day unless fluid‑restricted for cardiac/renal reasons.
• Consume high‑protein foods (lean meats, legumes, dairy) to preserve muscle mass.
• Vitamin D 800‑1000 IU daily is associated with better outcomes [JAMA, 2023].

Mental Health

Isolation, fatigue, and uncertainty can trigger anxiety or depression. Access tele‑therapy, mindfulness apps, or support groups. The CDC reports that 30 % of adults with COVID‑19 experience lasting mood changes [CDC, 2023].

Returning to Work/School

Most people can return after isolation if they feel well and have no fever for 24 hours. High‑risk settings (healthcare, long‑term care) may require a negative test before re‑entry.

Prevention

• Vaccination: Primary series + updated bivalent booster recommended for all ≥ 6 months. Vaccines reduce infection risk by ~50 % and severe disease by > 90 % [CDC, 2025].
• Masking: High‑filtration (N95/KN95) masks in crowded indoor spaces, especially during surges.
• Ventilation: Keep windows open, use HEPA filters, and limit time in poorly ventilated rooms.
• Hand hygiene: Wash hands with soap for at least 20 seconds or use alcohol‑based sanitizer (> 60 % ethanol).
• Testing before gatherings: Rapid antigen testing for symptomatic or exposed individuals.
• Prophylactic monoclonal antibodies: For immunocompromised patients unable to mount vaccine responses.

Complications

While most recover within weeks, COVID‑19 can lead to short‑ and long‑term complications.

• Respiratory: Acute respiratory distress syndrome (ARDS), persistent cough, fibrosis.
• Cardiovascular: Myocarditis, arrhythmias, heart failure, increased risk of thrombotic events (DVT, PE, stroke).
• Neurologic: Encephalopathy, seizures, “brain fog,” Guillain‑Barré syndrome.
• Renal: Acute kidney injury, which may progress to chronic kidney disease.
• Endocrine: New‑onset diabetes or worsening glycemic control.
• Post‑COVID syndrome (Long COVID): Fatigue, dyspnea, chest pain, dysautonomia lasting > 12 weeks; affects an estimated 10‑30 % of infected individuals [NIH, 2024].

When to Seek Emergency Care

---

References:

• World Health Organization. COVID‑19 Dashboard. 2026.
• Centers for Disease Control and Prevention. COVID‑19 Overview. Updated 2025.
• New England Journal of Medicine. “Paxlovid in Early COVID‑19.” 2022.
• RECOVERY Collaborative Group. “Dexamethasone in Hospitalized Patients with COVID‑19.” NEJM, 2020.
• JAMA. “Vitamin D Status and COVID‑19 Outcomes.” 2023.
• National Institutes of Health. Long COVID Research. 2024.
• Cleveland Clinic. COVID‑19: Symptoms and Treatment. 2025.

```